LSL Pharma Group Inc.
LSL.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 444.30% | 50.18% | 51.15% | 94.80% | 57.99% |
| Total Depreciation and Amortization | 89.24% | 0.31% | 17.57% | 34.55% | -18.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -222.18% | 8.48% | 95.82% | -87.42% | 605.66% |
| Change in Net Operating Assets | 86.36% | 78.79% | -290.25% | 23.34% | -1,674.71% |
| Cash from Operations | 3,263.54% | 96.47% | -1,267.16% | 58.92% | 100.55% |
| Capital Expenditure | 952.17% | -532.23% | -296.55% | -361.93% | -126.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -552.19% | -558.06% | -1,905.41% | -485.41% | -21.60% |
| Cash from Investing | -379.61% | -549.27% | -1,223.78% | -383.44% | -312.48% |
| Total Debt Issued | 692.76% | -40.27% | -47.54% | 214.50% | -73.05% |
| Total Debt Repaid | -232.65% | -480.00% | -229.94% | 84.63% | -2,152.63% |
| Issuance of Common Stock | -- | -- | -- | -79.02% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -163.02% | 40.74% | -84.82% | 83.07% | 256.61% |
| Cash from Financing | 285.62% | -36.33% | -- | -53.80% | -78.15% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 237.99% | 77.46% | 236.80% | -105.51% | 145.81% |